methyl bacteriopurpurinimide
Small moleculeexperimental
Clinical trial activity
1 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Nov 15, 2022 (NCT05363826)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Unspecified targetUnclear
unclear
Chemistry & pharmacology
Loading structure…
SMILES
CCCCOC(C)C1=C(C)C2=CC3=NC([C@@H](CCC(=O)OC)[C@@H]3C)=C4C5=NC(=CC6=NC(=CC1=N2)[C@H](C)[C@H]6CC)C(C)=C5C(=O)N(CCCC)C4=O- Mol. weight
- 707.9007 g/mol
Oral
No
Parenteral
No
Topical
No
Sources
- NCATSE7DBJ0SBC7 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05363826 | Phase 1 | Nov 15, 2022 | National Cancer Institute (NCI), Photolitec LLC, Roswell Park University, State University of New York, Buffalo |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2022 |
| Photolitec LLC | For profit | 1 | 1 | 1 | 2022 |
| Roswell Park University | Academic/Hospital | 1 | 0 | 1 | 2022 |
| State University of New York, Buffalo | Academic/Hospital | 1 | 0 | 1 | 2022 |
4 organizations
Page 1 / 1